Related Experiment Videos
Hypermagnesemia predicts mortality in elderly with congestive heart disease: relationship with laxative and antacid
Graziamaria Corbi1, Domenico Acanfora, Gian Luca Iannuzzi
1Rehabilitative Cardiology Unit of S. Maugeri Foundation, Scientific Institute of Telese/Campoli, IRCCS, Telese Terme, Italy. graziamaria.corbi@unina2.it
Insights
Higher magnesium levels are linked to reduced survival in elderly patients with congestive heart failure (CHF). This finding highlights the importance of monitoring magnesium in this vulnerable population.
Area of Science:
- Cardiology
- Geriatrics
- Clinical Biochemistry
Background:
- Congestive heart failure (CHF) is a prevalent condition in the elderly.
- Magnesium plays a crucial role in cardiac function.
- The prognostic significance of magnesium levels in elderly CHF patients requires further investigation.
Purpose of the Study:
- To evaluate the association between magnesium levels and 3-year survival in elderly patients with CHF.
- To identify potential risk factors and clinical characteristics associated with magnesium abnormalities in this population.
Main Methods:
- Retrospective analysis of 199 elderly patients (>=65 years) diagnosed with CHF.
- Clinical and instrumental examinations, including demographic data, co-morbidities, and mortality rates.
- Statistical analysis including univariate and multivariate models to assess the impact of magnesium levels on survival.
Main Results:
- Hypermagnesemia was present in 29.1% of the study cohort.
- Hypermagnesemia was associated with higher creatinine levels, greater disability, increased CHF mortality, and higher use of antacids/laxatives.
- Patients with higher magnesium levels demonstrated a significantly lower probability of 3-year survival.
Conclusions:
- Hypermagnesemia is a negative prognostic indicator in elderly patients with CHF, even without pre-existing renal failure.
- Physicians should carefully consider magnesium levels and potential medication interactions (laxatives, antacids) in managing elderly CHF patients.
Abstract:
The aim of this study was to evaluate the role of magnesium levels on 3-year survival in the elderly with congestive heart failure (CHF) admitted to the Rehabilitative Cardiology Unit of S. Maugeri Foundation Scientific Institute of Telese/Campoli. All elderly patients > or = 65 years old with a diagnosis of CHF underwent clinical and instrumental examination, and their demographics, co-morbidity, and in-hospital and 3-year mortality rates were recorded. Hypomagnesemia was found in 4.8%, normomagnesemia in 67.5%, and hypermagnesemia in 27.8% of subjects. The hypomagnesemic group was excluded for numerical exiguity; the analysis was performed on a total of 199 elderly patients. Hypermagnesemia was found in 29.1% and normomagnesemia in 70.9%. At the univariate analysis no differences were found in hypermagnesemia in respect to normomagnesemia group, except for slightly higher levels of creatininemia (1.35 +/- 0.61 vs. 1.13 +/- 0.55 mg/dL, respectively; p < 0.02), greater disability (lost ADL, 2.69 +/- 1.57 vs. 2.15 +/- 1.56, respectively; p < 0.05), more mortality for CHF (32.6 vs. 48.3%; p < 0.05), and higher antacid and laxative use (82.7 vs. 24.8%, respectively; p < 0.0001). Patients with higher magnesium showed less probability to survive at a 3-year follow-up than did patients with lower levels (17.32 +/- 15.93 vs. 22.46 +/- 16.16 months; p < 0.05), and this finding remained significant in the multivariate analysis after adjusting for some confounders. Finally hypermagnesemia should also be considered in the absence of pre-existing renal failure clinical evidence because of its negative prognostic value, especially in elderly patients with CHF. The shown relationship between hypermagnesemia and laxative/antacid use should induce physicians to pay more attention to abuse of these drugs.
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Heart Failure Drugs: Inotropic Agents
Heart Failure V: Medical Management
Heart Failure Drugs: Diuretics
Mitral Regurgitation IV: Nursing Management
Heart Failure VI: Adjunct Therapies